A Compassionate Use Study to Assess Narsoplimab for COVID-19 Patients
Latest Information Update: 04 Jun 2021
At a glance
- Drugs Narsoplimab (Primary)
- Indications Adult respiratory distress syndrome; COVID 2019 infections
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Sponsors Omeros Corporation
- 28 May 2021 Preliminary results (n=10) from the second cohort of critically ill COVID-19 patients treated with narsoplimab presented in an Omeros Corporation media release.
- 28 Oct 2020 According to an Omeros Corporation media release, results from this trial will be shared during a virtual event being hosted today for registered participants only by ROTH Capital Partners and presentation from the conference session can be viewed at https://investor.omeros.com/presentations.
- 17 Aug 2020 New trial record